289 related articles for article (PubMed ID: 35594744)
1. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K
Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744
[TBL] [Abstract][Full Text] [Related]
2. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.
Milano C; Turco F; Pizzanelli C; Bonanni E; Siciliano G; Fornai F; Giorgi FS
Epilepsy Behav; 2021 Feb; 115():107706. PubMed ID: 33423017
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy.
Sala-Padró J; Toledo M; Santamarina E; González-Cuevas M; Raspall-Chaure M; Sueiras-Gil M; Quintana M; Salas-Puig X
Clin Neuropharmacol; 2016; 39(6):299-301. PubMed ID: 27438183
[TBL] [Abstract][Full Text] [Related]
4. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
6. Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.
Tabrizi N; Zarvani A; Rezaei P; Cheraghmakani H; Alizadeh-Navaei R
Epilepsy Res; 2019 Nov; 157():106214. PubMed ID: 31627041
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy.
Gürer R; Aydın Ş; Özkara Ç
Seizure; 2019 Aug; 70():43-48. PubMed ID: 31252363
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy.
Ascoli M; Mastroianni G; Gasparini S; Striano P; Cianci V; Neri S; Bova V; Mammì A; Gambardella A; Labate A; Aguglia U; Ferlazzo E
Expert Rev Neurother; 2021 Nov; 21(11):1265-1273. PubMed ID: 33993822
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Seizure Recurrence in Women With Idiopathic Generalized Epilepsy Who Switch From Valproate to Another Medication.
Cerulli Irelli E; Cocchi E; Morano A; Gesche J; Caraballo RH; Lattanzi S; Strigaro G; Rosati E; Catania C; Ferlazzo E; Casciato S; Di Gennaro G; Pizzanelli C; Giuliano L; Viola V; Mostacci B; Pignatta P; Fortunato F; Pulitano P; Panzini C; Gambardella A; Atalar AÇ; Labate A; Operto FF; Giallonardo AT; Baykan BB; Beier CP; Di Bonaventura C;
Neurology; 2024 May; 102(9):e209222. PubMed ID: 38569127
[TBL] [Abstract][Full Text] [Related]
10. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI
Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379
[TBL] [Abstract][Full Text] [Related]
11. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
[TBL] [Abstract][Full Text] [Related]
12. Treatment of juvenile myoclonic epilepsy.
Auvin S
CNS Neurosci Ther; 2008; 14(3):227-33. PubMed ID: 18684236
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
Neurology; 2022 Sep; 99(10):e999-e1008. PubMed ID: 36219797
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam monotherapy in juvenile myoclonic epilepsy.
Sharpe DV; Patel AD; Abou-Khalil B; Fenichel GM
Seizure; 2008 Jan; 17(1):64-8. PubMed ID: 17692537
[TBL] [Abstract][Full Text] [Related]
17. Seizure outcome trajectories in a well-defined cohort of newly diagnosed juvenile myoclonic epilepsy patients.
Cerulli Irelli E; Morano A; Orlando B; Salamone EM; Fanella M; Fattouch J; Manfredi M; Giallonardo AT; Di Bonaventura C
Acta Neurol Scand; 2022 Mar; 145(3):314-321. PubMed ID: 34791656
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid.
Liguori C; Turner K; Izzi F; Assogna M; Canevini MP; Mercuri NB; Placidi F
CNS Neurosci Ther; 2019 May; 25(5):632-637. PubMed ID: 30675751
[TBL] [Abstract][Full Text] [Related]
19. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.
Calleja S; Salas-Puig J; Ribacoba R; Lahoz CH
Seizure; 2001 Sep; 10(6):424-7. PubMed ID: 11700996
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.
Gesche J; Hjalgrim H; Rubboli G; Beier CP
Epilepsy Res; 2021 Feb; 170():106547. PubMed ID: 33421702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
